Cedar Mountain Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$82.9K Hold
69
0.01% 123
2026
Q1
$63.6K Buy
69
+7
+11% +$7.1K 0.01% 120
2025
Q4
$66.7K Hold
62
0.01% 100
2025
Q3
$47.4K Buy
62
+52
+520% +$38.7K 0.01% 118
2025
Q2
$7.85K Sell
10
-16
-62% -$12.4K ﹤0.01% 230
2025
Q1
$21.6K Hold
26
﹤0.01% 149
2024
Q4
$20.1K Sell
26
-20
-43% -$16.6K ﹤0.01% 154
2024
Q3
$40.8K Buy
46
+16
+53% +$14.4K 0.01% 97
2024
Q2
$27.2K Sell
30
-3
-9% -$2.4K 0.01% 111
2024
Q1
$25.7K Hold
33
0.01% 120
2023
Q4
$19.2K Buy
33
+3
+10% +$1.75K 0.01% 133
2023
Q3
$16.1K Buy
+30
New +$15.5K ﹤0.01% 132

Other funds holding LLY

Cedar Mountain Advisors's LLY Position: Q2 2026 in Review

Cedar Mountain Advisors held its Eli Lilly (LLY) position steady in Q2 2026 at 69 shares worth $82.9K. The position accounts for 0.01% of the portfolio, ranked #123.

Cedar Mountain Advisors first reported a position in LLY in Q3 2023 and has held it in 12 quarters since. 841 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cedar Mountain Advisors held 69 shares of Eli Lilly worth $82.9K as of Q2 2026.
  • Cedar Mountain Advisors left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #123 holding.
  • Cedar Mountain Advisors first reported a position in Eli Lilly in Q3 2023 and has held it in 12 quarters since.
  • 841 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.